


I. Epidemiological profile

Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	1,030,000	4	Plasmodium species: <i>P. falciparum</i> (14%), <i>P. vivax</i> (78%)
Low transmission (0-1 cases per 1000 population)	12,600,000	44	Major anopheles species: <i>An. fluviatilis</i> , <i>An. annularis</i> , <i>An. maculatus</i>
Malaria-free (0 cases)	14,800,000	52	Reported confirmed cases (health facility): 647 Estimated cases: 24,000 [17,000 ; 35,000]
Total	28,510,000		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: <50 [-;-]


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2007	First-line treatment of unconfirmed malaria	CQ	-					
	ITNs/ LLINs distributed to all age groups	Yes	2007	First-line treatment of <i>P. falciparum</i>	AL+PQ	2004					
IRS	IRS is recommended	Yes	1962	Treatment failure of <i>P. falciparum</i>	AS; QN	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	-					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2004					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2009	Type pf RDT used		P.f + P.v specific (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	1962								
Treatment	ACT is free of charge for all ages in public sector	Yes	2005	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2015	AL	2005-2014	0	0	6.3	28 days	10	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2009	CQ	2008-2011	0	0	0	28 days	8	<i>P. vivax</i>
	G6PD test is a requirement before treatment with primaquine	Yes	-								
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	Yes	-								
Surveillance	ACD for case investigation (reactive)	Yes	2005	Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)							
	ACD of febrile cases at community level (pro-active)	Yes	2014	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	No	-	2014		Yes	No	No	An. annularis, An. fluviatilis, other		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	2014									


III. Financing




Government expenditure by intervention in 2015




IV. Coverage




Cases tested and treated in public sector




V. Impact



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

